Prices delayed by at least 15 minutes | Print
Novartis AG (NVS)
EquityThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Address
Lichtstrasse 35
Basel
CHE
4056
Telephone
+41 613247944
Forecast key dates
Name | Key Date |
---|---|
Novartis AG First Quarter Earnings Results for 2025 | 2025-04-23T00:00:00 |
Novartis AG First Quarter Earnings Conference Call for 2025 | 2025-04-23T00:00:00 |
Novartis AG Annual General Meeting for 2025 | 2025-03-05T00:00:00 |
Novartis AG Fourth Quarter Earnings Conference Call for 2024 | 2025-01-31T08:00:00 |
Novartis AG Fourth Quarter Earnings Results for 2024 | 2025-01-31T00:00:00 |
Novartis AG Annual Report for 2024 | 2025-01-31T00:00:00 |
Novartis AG Third Quarter Earnings Result for 2024 | 2024-10-29T00:00:00 |
Novartis AG Third Quarter Earnings Conference Call for 2024 | 2024-10-29T00:00:00 |
Novartis AG Second Quarter Earnings Result for 2024 | 2024-07-18T00:00:00 |
Novartis AG Second Quarter Earnings Conference Call for 2024 | 2024-07-18T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Novartis AG First Quarter Earnings Result for 2024 | 2024-04-23T00:00:00 |
Novartis AG First Quarter Earnings Conference Call for 2024 | 2024-04-23T00:00:00 |
Novartis AG Annual General Meeting for 2024 | 2024-03-05T00:00:00 |
Novartis AG Fourth Quarter Earnings Conference Call for 2023 | 2024-01-31T08:00:00 |
Novartis AG Fourth Quarter Earnings Result for 2023 | 2024-01-31T00:00:00 |
Novartis AG Annual Report for 2023 | 2024-01-31T00:00:00 |
Novartis R&D Investor Event | 2023-11-28T13:30:00 |
Novartis 10th annual ESG investor event | 2023-11-13T00:00:00 |
Novartis AG Third Quarter Earnings Conference Call for 2023 | 2023-10-24T14:00:00 |
Novartis AG Third Quarter Earnings Result for 2023 | 2023-10-24T00:00:00 |
Novartis AG Second Quarter Earnings Conference Call for 2023 | 2023-07-18T14:00:00 |
Novartis AG Second Quarter Earnings Result for 2023 | 2023-07-18T00:00:00 |
Sandos Capital Markets Days | 2023-06-08T09:00:00 |
ASCO Investor Event | 2023-06-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.